These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32972243)

  • 21. A structural feature of the non-peptide ligand interactions with mice mu-opioid receptors.
    Noori HR; Mucksch C; Urbassek HM
    Curr Comput Aided Drug Des; 2014; 10(4):354-60. PubMed ID: 25360566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
    Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
    Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen.
    Burford NT; Wehrman T; Bassoni D; O'Connell J; Banks M; Zhang L; Alt A
    J Biomol Screen; 2014 Oct; 19(9):1255-65. PubMed ID: 25047277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
    Spivak CE; Beglan CL; Seidleck BK; Hirshbein LD; Blaschak CJ; Uhl GR; Surratt CK
    Mol Pharmacol; 1997 Dec; 52(6):983-92. PubMed ID: 9415708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Encoding mu-opioid receptor biased agonism with interaction fingerprints.
    Hernández-Alvarado RB; Madariaga-Mazón A; Cosme-Vela F; Marmolejo-Valencia AF; Nefzi A; Martinez-Mayorga K
    J Comput Aided Mol Des; 2021 Nov; 35(11):1081-1093. PubMed ID: 34713377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH
    Gach-Janczak K; Piekielna-Ciesielska J; Adamska-Bartłomiejczyk A; Wtorek K; Ferrari F; Calo' G; Szymaszkiewicz A; Piasecka-Zelga J; Janecka A
    Peptides; 2018 Jul; 105():51-57. PubMed ID: 29684591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of μ-opioid receptor activation by acidic pH is dependent on ligand structure and an ionizable amino acid residue.
    Meyer J; Del Vecchio G; Seitz V; Massaly N; Stein C
    Br J Pharmacol; 2019 Dec; 176(23):4510-4520. PubMed ID: 31355457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular modeling and biological studies show that some μ-opioid receptor agonists might elicit analgesia acting as MMP-9 inhibitors.
    Ronsisvalle S; Spadaro A; Tomasello B; Basile L; Panarello F; Franchini S; Renis M; Guccione S; Crascì L; Panico AM
    Future Med Chem; 2019 Jun; 11(11):1245-1258. PubMed ID: 30974972
    [No Abstract]   [Full Text] [Related]  

  • 30. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
    Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
    García M; Virgili M; Alonso M; Alegret C; Farran J; Fernández B; Bordas M; Pascual R; Burgueño J; Vidal-Torres A; Fernández de Henestrosa AR; Ayet E; Merlos M; Vela JM; Plata-Salamán CR; Almansa C
    J Med Chem; 2020 Dec; 63(24):15508-15526. PubMed ID: 33064947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation.
    Jiang X; Li S; Zhang H; Wang LL
    Comput Biol Chem; 2021 Feb; 90():107405. PubMed ID: 33184004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, Pharmacological Evaluation, and Computational Studies of Cyclic Opioid Peptidomimetics Containing β
    Wtorek K; Lipiński PFJ; Adamska-Bartłomiejczyk A; Piekielna-Ciesielska J; Sukiennik J; Kluczyk A; Janecka A
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
    Ananthan S
    AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
    Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
    Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.
    Filizola M; Villar HO; Loew GH
    J Comput Aided Mol Des; 2001 Apr; 15(4):297-307. PubMed ID: 11349813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noribogaine is a G-protein biased κ-opioid receptor agonist.
    Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
    Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.
    Kennedy NM; Schmid CL; Ross NC; Lovell KM; Yue Z; Chen YT; Cameron MD; Bohn LM; Bannister TD
    J Med Chem; 2018 Oct; 61(19):8895-8907. PubMed ID: 30199635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.
    Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA
    Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.